Company
Team
CORPORATE GOVERNANCE
Platforms
Glycovirology
Degenerative Diseases
pipeline
ProLectin Pipeline
Degenerative Disease pipeline
Resources
IN THE NEWS
Stroke video
faq
SCIENTIFIC PUBLICATIONS
investors
Company presentation
press releases
Reports
financial
Contact US
$BIXT
Company
Platforms
Glycovirology
Degenerative Diseases
Resources
Investors
Pipeline
contact us
Glycovirology Scientific Publications
featured
Galectin approach to lower covid transmission - Drug Development for clinical use
Galectin approach to lower covid transmission - Drug Development for clinical use
Galectins in tumour immunity
Galectins in tumour immunity
Dr. Nambier on the Development of Galectin-1 for Head and Neck Cancer
Dr. Nambier on the Development of Galectin-1 for Head and Neck Cancer
Previous
load more
Galectin-3 as a potential prognostic biomarker of severe COVID-19 in SARS-CoV-2 infected patients.
Galectin-3 as a potential prognostic biomarker of severe COVID-19 in SARS-CoV-2 infected patients.
Serum Galectin-3 and Aldosterone: potential biomarkers of cardiac complications in patients with COVID-19
Serum Galectin-3 and Aldosterone: potential biomarkers of cardiac complications in patients with COVID-19
The SARS-CoV-2 receptor-binding domain preferentially recognizes blood group A
The SARS-CoV-2 receptor-binding domain preferentially recognizes blood group A
Computational Study of Potential Galectin-3 Inhibitors in the Treatment of COVID-19
Computational Study of Potential Galectin-3 Inhibitors in the Treatment of COVID-19
Previous
load more
go back